首页> 外文期刊>Microbiology and Immunology >A new approach to AIDS research and prevention: the use of gene-mutated HIV-1/SIV chimeric viruses for anti-HIV-1 live-attenuated vaccines.
【24h】

A new approach to AIDS research and prevention: the use of gene-mutated HIV-1/SIV chimeric viruses for anti-HIV-1 live-attenuated vaccines.

机译:艾滋病研究和预防的新方法:将基因突变的HIV-1 / SIV嵌合病毒用于抗HIV-1减毒活疫苗。

获取原文
获取原文并翻译 | 示例
           

摘要

The lack of a suitable animal model is a major obstacle to developing anti-HIV-1 vaccines. We successfully generated an SIVmac/HIV-1 chimeric virus (SHIV) (designated as NM-3rN) that contains the HIV-1 env gene and is infectious to macaque monkeys. Challenging the vaccinated macaque monkeys with NM-3rN, we developed an evaluation system for anti-HIV-1 Env-targeted vaccines. For the purpose of making the vaccine, a series of gene-mutated SHIVs were constructed. The monkeys vaccinated with these SHIVs had long-term anti-virus immunities without manifesting the disease, and became resistant to a challenge inoculation with NM-3rN. The sera from a monkey showed that, after the vaccination, the neutralizing antibodies not only against the parental HIV-1 but also against an antigenically different HIV-1 were raised. In vivo experiments confirmed that the vaccinated monkeys were protected from the challenge inoculum of an antigenically different SHIV-MN. Vaccination of monkeys with the attenuated SHIVs showed that further gene-deletion of the SHIV resulted in less immunogenicity. Nevertheless, the attenuated SHIVs had a vaccine effect against the challenge inoculation. In addition to specific immunities including neutralizing antibodies and cytotoxic T cells, a more complicated immune mechanism induced by live vaccine appears to play a role in this protection. Our data suggest that the live vaccine can induce strong and wide-range immunity against HIV-1. These SHIVs should contribute to understanding the pathogenicity of AIDS and to the development of future anti-HIV-1 live vaccines for humans.
机译:缺乏合适的动物模型是开发抗HIV-1疫苗的主要障碍。我们成功地产生了一个包含HIV-1 env基因并感染猕猴的SIVmac / HIV-1嵌合病毒(SHIV)(命名为NM-3rN)。用NM-3rN挑战接种猕猴,我们开发了针对HIV-1 Env靶向疫苗的评估系统。为了制备疫苗,构建了一系列基因突变的SHIV。接种了这些SHIVs的猴子具有长期的抗病毒免疫能力,而没有表现出这种疾病,并且对使用NM-3rN进行的挑战接种具有抗性。猴子的血清显示,接种疫苗后,不仅产生了针对亲代HIV-1的中和抗体,而且还产生了针对抗原性不同的HIV-1的中和抗体。体内实验证实,接种过的猴子可以免受抗原性不同的SHIV-MN的攻击接种。用减毒的SHIV疫苗接种猴子表明,进一步删除SHIV基因导致免疫原性降低。尽管如此,减毒的SHIVs仍具有针对挑战接种的疫苗作用。除了包括中和抗体和细胞毒性T细胞在内的特异性免疫,由活疫苗诱导的更复杂的免疫机制似乎在这种保护中起作用。我们的数据表明,活疫苗可以诱导针对HIV-1的强大而广泛的免疫力。这些SHIV应该有助于理解AIDS的致病性,并为未来的人类抗HIV-1活疫苗的开发做出贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号